The GLOW study confirms data from CAPTIVATE for CLL / SLL patients over 65 years of age and patients with comorbidity

Prof Arnon Cater, Amsterdam University Medical Center, presented as a late breaking abstract at EHA 2021. The results show that elderly patients and younger patients with comorbidity also benefit from the combination of ibrutinib and venetoclax in a fixed duration regime.